Researcher Spotlight: Wendy Béguelin, PhD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY Follicular lymphoma (FL) is a clinically heterogenous disease. For some patients, tumors are slow growing and outcomes are favorable; others experience a high-risk, rapidly progressing disease that is associated…
Researcher Spotlight: Matthew Maurer, D.M.Sc MAYO CLINIC, ROCHESTER Follicular lymphoma (FL) is a heterogeneous disease characterized by episodes of relapse and transformation. Prognostic models exist that can be applied at diagnosis to predict how the disease will progress and what…
Researcher Spotlight: Joshua Brody, MD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies, have revolutionized the treatment of follicular lymphoma (FL), but many patients still relapse. Antigen escape is…
Researcher Spotlight: Edward Dominguez, PhD BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE HEALTH EQUITY INITIATIVE Cyclin-dependent kinases, including CDK9, are responsible for regulation of a variety of cellular processes that contribute to the growth and expansion of cancer cells. Using…
Researcher Spotlight: Ajlan Al Zaki, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chimeric antigen receptor (CAR) T-cell therapies represent a meaningful treatment option for lymphoma, but many patients who receive these therapies will experience side effects caused by…
Researcher Spotlight: Christopher Sauter, MD PERELMAN SCHOOL OF MEDICINE, UNIVERSITY OF PENNSYLVANIA Chimeric antigen receptor (CAR) T-cell therapies work by harnessing the power of T cells to kill lymphoma cells through a variety of cytotoxic mechanisms that are coordinated simultaneously.…
Researcher Spotlight: Yifei Liao, PhD BRIGHAM AND WOMEN’S HOSPITAL Several types of lymphomas have been associated with Epstein-Barr virus (EBV) infection. Little is known about how EBV manipulates cellular processes in lymphoma, though, including how it evades detection by the…
Researcher Spotlight: Anouchka Laurent, PhD COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK Understanding the mechanisms and molecules involved in the formation of T-cell lymphomas (TCL) can illuminate new potential targets for drug development. Dr. Laurent’s research is focused on…
Researcher Spotlight: Sanket Shah, PhD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY DR. BRUCE D. CHESON FELLOW Diffuse large B-cell lymphomas (DLBCL) are a heterogeneous group of lymphomas associated with poor outcomes and high rates of mortality. Mutations in genes that…
Researcher Spotlight: Tayla Heavican-Foral, PhD DANA-FARBER CANCER INSTITUTE DR. OLIVER PRESS MEMORIAL FELLOW HEALTH EQUITY INITIATIVE Despite treatment advances in the lymphoma space, many patients with T-cell lymphomas (TCL) still experience limited response rates, often lasting for short durations, with…